Anthropicの新戦略：バイオテックにツールを売り、自ら薬を開発する
Anthropicは「Claude Science」を立ち上げ、顧みられない疾患（neglected diseases）の薬の発見計画を発表。ツールの販売から、製薬分野における直接的な競合への転換を示している。
anthropic introduced claude science, an integrated workbench for scientists, and declared its intent to develop proprietary drugs, focusing on neglected diseases. while the firm lists major biotech clients, this move pits it against partners like pfizer and merck, creating a complex vendor-customer dynamic. anthropic provided few details on clinical trials or manufacturing, but this escalation mirrors trends by google's isomorphic labs. the strategy proves that frontier labs are moving beyond text generation into high-stakes, real-world biology applications where failures can cost billions.